MA31999B1 - Proteines de liaison a l'antigene - Google Patents

Proteines de liaison a l'antigene

Info

Publication number
MA31999B1
MA31999B1 MA32987A MA32987A MA31999B1 MA 31999 B1 MA31999 B1 MA 31999B1 MA 32987 A MA32987 A MA 32987A MA 32987 A MA32987 A MA 32987A MA 31999 B1 MA31999 B1 MA 31999B1
Authority
MA
Morocco
Prior art keywords
amyloid
antigen
binding proteins
diseases
methods
Prior art date
Application number
MA32987A
Other languages
Arabic (ar)
English (en)
Inventor
Philippe Marc Louis Alard
Jonathan Henry Ellis
Susannah Karen Ford
Volker Germaschewski
Alan Peter Lewis
Peter Ernest Soden
Pamela Joan Thomas
Trevor Anthony Kenneth Wattam
Ian Richard Catchpole
Gerald Wayne Gough
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40547800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31999(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0724185A external-priority patent/GB0724185D0/en
Priority claimed from GB0806230A external-priority patent/GB0806230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA31999B1 publication Critical patent/MA31999B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des protéines de liaison à l'antigène qui se lient au peptide ²-amyloïde, en particulier au peptide ²-amyloïde humain; des méthodes utilisant ces protéines de liaison à l'antigène pour traiter des maladies ou des troubles caractérisés par des taux élevés de ²-amyloïde ou des dépôts ²-amyloïdes, notamment la maladie d'alzheimer et des maladies ou des troubles affectant l'sil ou le nerf optique et qui sont caractérisés par des taux élevés de ²-amyloïde ou des dépôts ²-amyloïdes, y compris la dégénérescence maculaire liée à l'âge et des maladies du type glaucome et la formation de cataracte dépendant des protéines ²-amyloïdes; des compositions pharmaceutiques comprenant ces protéines de liaison à l'antigène; et des procédés de fabrication.
MA32987A 2007-12-11 2010-07-05 Proteines de liaison a l'antigene MA31999B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0724185A GB0724185D0 (en) 2007-12-11 2007-12-11 Antibodies
GB0806230A GB0806230D0 (en) 2008-04-04 2008-04-04 Antibodies
US4383908P 2008-04-10 2008-04-10
PCT/EP2008/067138 WO2009074583A1 (fr) 2007-12-11 2008-12-09 Protéines de liaison à l'antigène

Publications (1)

Publication Number Publication Date
MA31999B1 true MA31999B1 (fr) 2011-01-03

Family

ID=40547800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32987A MA31999B1 (fr) 2007-12-11 2010-07-05 Proteines de liaison a l'antigene

Country Status (24)

Country Link
US (2) US20110014182A1 (fr)
EP (1) EP2222705B1 (fr)
JP (2) JP5512537B2 (fr)
KR (2) KR101629365B1 (fr)
CN (1) CN101970484B (fr)
AR (1) AR069610A1 (fr)
AU (1) AU2008334637B2 (fr)
BR (1) BRPI0819916A2 (fr)
CA (1) CA2707859A1 (fr)
CL (1) CL2008003655A1 (fr)
CO (1) CO6280540A2 (fr)
CR (1) CR11561A (fr)
DO (1) DOP2010000170A (fr)
EA (1) EA022913B1 (fr)
ES (1) ES2525704T3 (fr)
IL (1) IL206188A0 (fr)
MA (1) MA31999B1 (fr)
MX (1) MX2010006422A (fr)
NZ (1) NZ586003A (fr)
PE (1) PE20091449A1 (fr)
TW (1) TWI388334B (fr)
UY (1) UY31520A1 (fr)
WO (1) WO2009074583A1 (fr)
ZA (1) ZA201004133B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2586795B1 (fr) 2007-10-05 2018-05-16 Genentech, Inc. Utilisation d'anticorps anti-beta amyloide aux maladies oculaires
EP2538929A4 (fr) 2010-02-25 2014-07-09 Univ Johns Hopkins Délivrance prolongée d'agents thérapeutiques à un compartiment oculaire
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
EP2694109A4 (fr) * 2011-04-07 2015-02-18 Neotope Biosciences Ltd Compositions et procédés pour traiter des maladies d'agrégation de protéines impliquant un dépôt d'ic3b
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
JP2015504674A (ja) * 2012-01-11 2015-02-16 アリゾナ ボード オブ リージェンツ ア ボディ コーポレート オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ， Ａ Ｂｏｄｙ Ｃｏｒｐｏｒａｔｅ Ｏｆ Ｔｈｅ Ｓｔａｔｅ Ｏｆ Ａｒｉｚｏｎａ Ａｃｔｉｎｇ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 神経疾患タンパク質の二重特異性抗体フラグメントおよび使用方法
BR112016000106B1 (pt) 2013-07-09 2023-11-21 Annexon, Inc. Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados
WO2015061668A1 (fr) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux anti-pd-l1 et fragments de ceux-ci
AU2015213593B2 (en) * 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
WO2016073685A1 (fr) * 2014-11-05 2016-05-12 Annexon, Inc. Anticorps humanisés anti-facteur du compément c1q et leurs utilisations
WO2017035405A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amino pour le traitement de troubles immunitaires et inflammatoires
WO2017035409A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés aryle, hétéroaryle, et hétérocycliques pour le traitement de troubles immunitaires et inflammatoires
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amide pour le traitement de troubles immunitaires et inflammatoires
EP3380518B1 (fr) 2015-11-24 2026-03-25 Annexon, Inc. Fragments fab anti-complément de facteur c1q et leurs utilisations
CA3011819A1 (fr) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions et procedes pour inhiber le facteur d
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
JP7173965B2 (ja) * 2016-10-19 2022-11-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 試料中の非結合Ｃ５ａの定量化方法
JP7096240B2 (ja) * 2016-10-19 2022-07-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 試料中の非結合ｃ５の定量化方法
WO2018136827A1 (fr) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Compositions à boucle en épingle à cheveux et procédés pour inhiber le facteur d
WO2018160891A1 (fr) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Composés pharmaceutiques destinés au traitement de troubles médicaux
US20200330592A1 (en) * 2017-10-09 2020-10-22 Keith Black Compositions and methods of treating alzheimer's and other amyloid related diseases
EP3847174A4 (fr) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. Formes morphiques d'inhibiteurs du facteur d du complément
JP7471300B2 (ja) 2018-12-17 2024-04-19 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体介在性疾患を治療するための的を絞った投与
EP3941462A4 (fr) 2019-03-22 2023-04-05 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques pour le traitement de troubles médiés par le complément
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
WO2021183555A1 (fr) * 2020-03-10 2021-09-16 Achillion Pharmaceuticals, Inc. Dépôt de médicament oculaire pour troubles à médiation par le complément
JP2021141861A (ja) * 2020-03-13 2021-09-24 富士フイルム和光純薬株式会社 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法
CN113929748B (zh) * 2020-07-13 2023-10-20 中国科学技术大学 检测bace1酶活性的试剂盒及用途
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
EP4676980A2 (fr) * 2023-03-03 2026-01-14 Case Western Reserve University Immunothérapies ciblant une molécule d'adhésion cellulaire
CN117131608B (zh) * 2023-10-23 2024-03-15 南京航空航天大学 一种基于最佳环量分布的激励盘方法
CN118258998B (zh) * 2024-05-31 2024-08-09 北京大学人民医院 一种抗原特异性b细胞检测探针及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017197A1 (fr) * 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
AU5286999A (en) * 1999-07-23 2001-02-13 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
EP1480666B1 (fr) 2002-03-05 2012-06-13 Ramot at Tel-Aviv University Ltd. Composition immunisante et procede permettant d'induire une reponse immunitaire contre le site de clivage de beta-secretase de la proteine precurseur amyloide
PL377769A1 (pl) * 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
WO2007113172A2 (fr) * 2006-03-30 2007-10-11 Glaxo Group Limited Anticorps
US20090022728A1 (en) * 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases

Also Published As

Publication number Publication date
JP2011506387A (ja) 2011-03-03
CR11561A (es) 2010-09-23
CO6280540A2 (es) 2011-05-20
DOP2010000170A (es) 2010-08-15
KR101657637B1 (ko) 2016-09-19
PE20091449A1 (es) 2009-10-07
CA2707859A1 (fr) 2009-06-18
BRPI0819916A2 (pt) 2015-05-19
EP2222705B1 (fr) 2014-10-22
CN101970484A (zh) 2011-02-09
NZ586003A (en) 2012-08-31
AR069610A1 (es) 2010-02-03
TWI388334B (zh) 2013-03-11
KR20150100964A (ko) 2015-09-02
EP2222705A1 (fr) 2010-09-01
CN101970484B (zh) 2014-10-01
US20110014182A1 (en) 2011-01-20
AU2008334637A1 (en) 2009-06-18
EA201000787A1 (ru) 2010-12-30
EA022913B1 (ru) 2016-03-31
ZA201004133B (en) 2011-11-30
ES2525704T3 (es) 2014-12-29
JP5512537B2 (ja) 2014-06-04
TW200932267A (en) 2009-08-01
KR20100099277A (ko) 2010-09-10
IL206188A0 (en) 2010-12-30
CL2008003655A1 (es) 2010-04-16
JP2014177462A (ja) 2014-09-25
US8921523B2 (en) 2014-12-30
KR101629365B1 (ko) 2016-06-14
AU2008334637B2 (en) 2014-08-07
UY31520A1 (es) 2009-08-03
US20090162358A1 (en) 2009-06-25
WO2009074583A1 (fr) 2009-06-18
MX2010006422A (es) 2010-06-25

Similar Documents

Publication Publication Date Title
MA31999B1 (fr) Proteines de liaison a l'antigene
MA30337B1 (fr) Anticorps
JP6125430B2 (ja) 低親和性血液脳関門受容体抗体及びその使用
PH12011502389A1 (en) Monoclonal antibody
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
EA201100654A1 (ru) Соединения для лечения офтальмологических заболеваний и расстройств
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
WO2006091796A3 (fr) Compositions et methodes destinees au diagnostic et au traitement de maladies retiniennes
MA53765A1 (fr) Tubulysines et conjugués tubulysines-protéines
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
EP2213684A3 (fr) Anticorps nogo-a pour le traitement de la maladie d'Alzheimer
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
JP2025037985A (ja) 改変抗体ｆｃおよび使用方法
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines
EA201100462A1 (ru) Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств
US20130149237A1 (en) Delivery system for diagnostic and therapeutic agents
DE602004010314D1 (de) Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren
WO2006110367A3 (fr) Procedes et compositions pour toxines mycoplasma
MA35580B1 (fr) Composition pharmaceutique
CY1115021T1 (el) Μονοκλωνικα αντισωματα εναντι αμυλοειδους βητα πρωτεϊνης και χρησεις αυτων